ArticleFrontiers in immunology2026
Radiotherapy combined with immunotherapy achieves clinical complete response in elderly metastatic penile cancer: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A combination of local and systemic therapies is used to treat inguinal lymph node metastases post-penile cancer surgery. This multimodal approach may include surgery, chemotherapy, radiotherapy, and immunotherapy. Case summary: We describe an 89-year-old male with a history of penile cancer status post resection, who presented with multiple metastases to the left inguinal lymph nodes confirmed by pathological biopsy. The patient was treated with a combination of radiotherapy and Pembrolizumab. Following this combined modality therapy, he experienced symptomatic relief and achieved a progression-free survival exceeding 38 months. Conclusion: This case suggests that concurrent radiotherapy plus Pembrolizumab may achieve durable remission in elderly, chemotherapy-intolerant, metastatic PSCC, but verification in more patients is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.